The accurate genetic counseling of dystrophinopathies relies primarily on the identification of underlying disease-causing DMD variants in the affected patients and the determination of the carrier status in the family (Kubota et al., 2022). This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.